Printer Friendly

WARNER-LAMBERT REPORTS RECORD SALES AND EARNINGS IN SECOND QUARTER

 WARNER-LAMBERT REPORTS RECORD SALES AND EARNINGS IN SECOND QUARTER
 MORRIS PLAINS, N.J., July 21 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) today reported that sales, earnings per share (EPS) and net income for the three months ended June 30, 1992, all were a record for any quarter.
 Worldwide sales increased 11 percent (also 11 percent at constant currency rates) to $1.37 billion from $1.24 billion during the second quarter of 1991. Earnings per share in the second quarter increased 15 percent to $1.32, compared with $1.15 during the same period a year earlier; and net income increased 15 percent to $178 million, compared with $155 million during the same period last year.
 Melvin R. Goodes, chairman and chief executive officer, said the company's healthy sales and earnings gains were the result of continuing strong worldwide sales of prescription pharmaceuticals and a resurgence in the consumer products business, whose growth had been hampered by the recessionary U.S. economy and the short-term impact of major sales force realignments.
 During the second quarter, worldwide sales within the Pharmaceutical Sector increased 18 percent. Sales increased more than 18 percent in the U.S. and more than 17 percent in markets outside the U.S. Sector growth was led by Lopid, whose sales rose by more than 16 percent to $131 million. The sector includes prescription pharmaceutical products and empty hard gelatin Capsugel capsules. Among the company's other prescription pharmaceuticals are the anticonvulsant Dilantin, the cardiovascular drugs Accupril and Dilzem, the analgesic Ponstel, Loestrin oral contraceptives and the anti-infectives Doryx and Eryc.
 Worldwide sales within the Consumer Sector increased by 7 percent. Sales rose by 6 percent in the U.S. and by more than 7 percent outside the U.S. Driving segment growth were two new products, Cool Mint Listerine mouthwash and Cinn-A-Burst chewing gum, as well as Clorets gum and mints and Tetra pet care products. The company's line of consumer products also includes Halls cough tablets, Listerine antiseptic mouthwash, Lubriderm skin care products, Benadryl antihistamine, Rolaids antacid, Schick razors and blades, Sinutab sinus medication, Tucks medicated pads, Anusol hemorrhoidal preparation, Efferdent denture cleanser, Trident sugarless gum, Bubblicious bubble gum, Certs breath mints, Dentyne chewing gum, Chiclets candy coated gum and chocolate/caramel brands including Junior Mints.
 In important recent developments, the company:
 -- confirmed that Nicotrol (nicotine transdermal system), the only nicotine patch designed specifically to be worn during waking hours, would be introduced during August. Nicotrol, co-developed by Kabi Pharmacia of Sweden and Cygnus Therapeutic Systems Inc. of California, is being manufactured by Cygnus and will be marketed in the U.S. by the Parke-Davis division of Warner-Lambert. Parke-Davis said it has formed a nationwide partnership with Smoke Stoppers, a behavioral support system used by approximately 350 medical centers, corporations and labor organizations nationwide. Nicotrol is intended for use as part of a comprehensive behavioral smoking cessation program.
 -- said enrollment in its expanded access ("Treatment IND") program for the experimental Alzheimer's drug Cognex had begun to accelerate. The first phase of the program reached its goal of enlisting approximately 1,500 physicians and more than 1,900 patients had begun to receive drug therapy as part of the program's second phase, which ultimately could expand use of the drug to as many as 15,000 patients nationwide.
 -- completed enrollment in a clinical study of Cognex (970-61) involving higher doses and a longer duration of treatment. The study was undertaken at the request of the Peripheral and Central Nervous System advisory committee to the FDA in July, 1991.
 -- for the first time presented results of a parallel design, multicenter U.S. trial of Cognex (970-26) at the Third International Congress on Alzheimer's Disease in Italy on July 17. The data, from trials with the drug as high as 80 mg. a day, showed statistically significant outcomes on both primary outcome measures, satisfying prospectively defined criteria for establishing efficacy. The primary measures included the Alzheimer's Disease Assessment Scale (cognitive subscale) and the investigator-rated Clinical Global Impressions of Change. Results on a caregiver-rated global impression of change scale were also statistically significant.
 -- reported that the launch of Cool Mint Listerine continues to be very encouraging. The product has received enthusiastic trade and consumer acceptance, based on the combination of its traditional germ- killing capability and refreshingmint taste. Cool Mint Listerine and parent Listerine are the only leading brands to carry the Seal of Acceptance of the American Dental Association for helping to fight dental plaque and gingivitis.
 Warner-Lambert is a worldwide company devoted to developing, manufacturing and marketing quality health care and consumer products. It employs approximately 34,000.
 WARNER-LAMBERT COMPANY
 Three months ended June 30, 1992 1991
 Sales $1,373,344,000 $1,238,233,000
 Research and development 105,866,000 101,424,000
 Income before federal, state
 and foreign income taxes 238,796,000 210,426,000
 Net income 177,822,000 154,573,000
 Earnings per share $1.32 $1.15
 Average number of common
 shares outstanding 134,630,000 134,400,000
 Six months ended June 30, 1992 1991
 Sales $2,684,870,000 $2,455,428,000
 Research and development 220,969,000 196,141,000
 Income before federal, state
 and foreign income taxes 461,420,000 402,865,000
 Net income before accounting
 change 341,451,000 294,091,000
 Accounting change (net of tax) -- (106,000,000)(A)
 Net income 341,451,000 188,091,000(A)
 Earnings per share $2.54 $1.40(A)
 Average number of common
 shares outstanding 134,619,000 134,382,000
 (A) -- Includes the accounting change of $146 million ($106 million after-tax or $.79 per share) reflecting the adoption of Statement of Financial Accounting Standards No. 106, "Employers' Accounting for Postretirement Benefits Other Than Pensions," recorded retroactively as of Jan. 1, 1991. Excluding the accounting change, earnings per share for the first six months of 1991 were $2.19.
 -0- 7/21/92
 /CONTACT: Peter Wolf, 201-540-6696, or Sandy Horner, 201-540-4268; or (investors) Stephen Mock, 201-540-6916, or Cary Rosansky, 201-540-4874, all of Warner-Lambert/
 (WLA) CO: Warner-Lambert Company ST: New Jersey IN: MTC SU: ERN


TS -- NY027 -- 1160 07/21/92 09:36 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:1026
Previous Article:AMERICAN PRECISION ANNOUNCES 2ND QUARTER EARNINGS
Next Article:PIPER JAFFRAY REPORTS THIRD QUARTER EARNINGS
Topics:


Related Articles
WARNER-LAMBERT ACHIEVES RECORD SALES; RAISES DIVIDEND 16 PERCENT
WARNER-LAMBERT CEO GOODES SAYS SECOND-QUARTER SALES TO RISE BY MORE THAN 8 PERCENT
WARNER-LAMBERT REPORTS RECORD SALES IN THIRD QUARTER
WARNER-LAMBERT REPORTS THIRD-QUARTER SALES AND EARNINGS
WARNER-LAMBERT REPORTS SECOND-QUARTER SALES AND EARNINGS
WARNER-LAMBERT REPORTS THIRD-QUARTER SALES AND EARNINGS
WARNER-LAMBERT REPORTS SECOND QUARTER GAIN OF 9% PBT ON SALES INCREASE OF 16%
WARNER-LAMBERT REPORTS SECOND QUARTER GAIN OF 6% PBT AND 5% EPS ON REVENUE OF $1.8 BILLION
Warner-Lambert Reports First Quarter Sales and Earnings
Warner-Lambert Reports Second Quarter Gain of 8% EPS on Sales Increase of 10%

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters